Frequency Therapeutics
The Woburn, Massachusetts-based firm aims at developing a treatment for sensorineural hearing loss (SNHL), which is the most common type of hearing loss. The disorder reportedly affects over 59 million people in the US alone.
The drug candidate – FX-322 – will begin Phase 2a clinical trial by the end of this year, results of which are expected by mid next 2020. Currently, SNHL does not have any FDA-approved drug therapies in the market. In the future, Frequency hopes to expand its proprietary approach, which it calls Progenitor Cell Activation, to other degenerative conditions such as multiple sclerosis.
On Thursday, the company floated 6 million shares for $14 apiece under the ticker FREQ, but the stock ended its first trading day down 2%.
Aprea Therapeutics
Aprea Therapeutics is
a more promising stock. It is an oncology-focused biopharmaceutical firm and
its lead product candidate, APR-246 is currently undergoing Phase 3 trial.
Notably, it has received orphan drug status from both the FDA and the European
Medicines Agency for the treatment of myelodysplastic syndromes (MDS), a type
of cancer.
APR-246 also has a Fast Track designation from the FDA.
The company aims to
treat cancer by reactivating mutant p53 tumor suppressor protein, which in its
normal state functions to sense DNA damage and induce cell cycle arrest.
The company issued 5.7 million shares for $15 a share, and the stock ended its first trading day up at $20.50. The company, headquartered in Boston, is trading under the ticker APRE.
Get access to timely and accurate
verbatim transcripts that are published within hours of the event.